Gå direkt till huvudinnehållet

Riskskattning och förebyggande av hjärt-kärlsjukdom

Senast uppdaterad: Senast reviderad:


  1. Brunström M, Andersson J, Eliasson M, et al. SCORE2 – ett uppdaterat verktyg för att skatta kardiovaskulär risk. Läkartidningen. 2021;118:21164. lakartidningen.se  
  2. Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med 2022; 387: 1385-94. pmid:36027560 PubMed  
  3. Lin JS, Evans CV, Johnson E, et al. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320: 281-97. pmid:29998301 PubMed  
  4. Bell KJL, White S, Hassan O, et al. Evaluation of the Incremental Value of a Coronary Artery Calcium Score Beyond Traditional Cardiovascular Risk Assessment: A Systematic Review and Meta-analysis. JAMA Intern Med 2022. pmid:35467692 PubMed  
  5. Läkemedelsverket (2014). Aterosklerotisk hjärt-kärlsjukdom. (Hämtad 2016-06-30). lakemedelsverket.se  
  6. McNeil JJ, Wolfe R, Woods RL et al . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.. N Engl J Med 2018; 379: 1509-18. pmid:30221597 PubMed  
  7. Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events A Systematic Review and Meta-analysis. JAMA 2019; 321: 277-87. pmid:30667501 PubMed  
  8. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018. pmid:30146931 PubMed  
  9. Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol 2019; 18(1): 70. pmid:31159806 PubMed  
  10. Biddinger KJ, Emdin CA, Haas ME, et al. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Netw Open. 2022;5(3):e223849. PMID:35333364. PubMed  
  11. Rees K, Al-Khudairy L, Takeda A, et al. Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases. Cochrane Database Syst Rev. 2021 Feb 25;2:CD013501. doi: 10.1002/14651858.CD013501.pub2. DOI  
  12. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk The STRENGTH Randomized Clinical Trial. JAMA 2020. PMID:33190147. PubMed  
  13. Mohan D, Mente A, Dehghan M, et al. Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries published online ahead of print, 2021 Mar 8. JAMA Intern Med. 021;10.1001/jamainternmed.2021.0036. PMID:33683310. PubMed  
  14. Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195-1205. doi:10.1016/S0140-6736(22)01657-9 DOI  
  15. SBU. Befolkningsscreening av riskfaktorer och livsstilsförändrande samtalsstöd som prevention för hjärt- och kärlsjukdomar. 2019-12-20 (Hämtad 2020-01-16). www.sbu.se  
  16. Dehghan M, Mente A, Rangarajan S, et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2018; 392: 2288-97. pmid:30217460. www.ncbi.nlm.nih.gov  
  17. Jayedi A, Soltani S, Zargar MS, et al. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 2020; 370: m3324. pmid:32967840 PubMed  
  18. Ma Y, He FJ, Sun Q, et al. 24-hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med 2021. PMID: 34767706 PubMed  
  19. Ma H, Xue Q, Wang X, et al. Adding salt to foods and hazard of premature mortality. Eur Heart J. 2022;43(30):2878-2888. PMID:35808995. PubMed  
  20. Joseph P, Roshandel G, Gao P, et alq. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021. pmid:34469765 PubMed  
  21. Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395(10235):1487‐1495. PMID:32386592. PubMed